Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|June 1, 1997
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)B Thürlimann, M Castiglione, S F Hsu-Schmitz, et al.
The Pharmacogenomics Journal|June 25, 2014
Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trialV Le Morvan, S Litière, A Laroche-Clary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?J Bernhard, B Thürlimann, S F Schmitz, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 1999
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)J Bernhard, M Castiglione-Gertsch, S F Schmitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter studyP Therasse, L Mauriac, M Welnicka-Jaskiewicz, et al.
Breast Cancer Research and Treatment|June 1, 2000
Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatmentM E Sabbioni, H P Siegrist, M Bacchi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2009
Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trialS Mook, H Bonnefoi, G Pruneri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Telomerase RNA as a detection marker in the serum of breast cancer patientsX Q Chen, H Bonnefoi, M F Pelte, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 21, 1999
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patientsM E Sabbioni, M Castiglione, C Hürny, et al.
Breast (Edinburgh, Scotland)|September 22, 2015
Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective studyD Chocteau-Bouju, C Chakiba, L Mignot, et al.
Pageof 5